371 related articles for article (PubMed ID: 29506908)
1. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.
Tasfaout H; Lionello VM; Kretz C; Koebel P; Messaddeq N; Bitz D; Laporte J; Cowling BS
Mol Ther; 2018 Apr; 26(4):1082-1092. PubMed ID: 29506908
[TBL] [Abstract][Full Text] [Related]
2. Reducing dynamin 2 (DNM2) rescues
Buono S; Ross JA; Tasfaout H; Levy Y; Kretz C; Tayefeh L; Matson J; Guo S; Kessler P; Monia BP; Bitoun M; Ochala J; Laporte J; Cowling BS
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11066-11071. PubMed ID: 30291191
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.
Tasfaout H; Buono S; Guo S; Kretz C; Messaddeq N; Booten S; Greenlee S; Monia BP; Cowling BS; Laporte J
Nat Commun; 2017 Jun; 8():15661. PubMed ID: 28589938
[TBL] [Abstract][Full Text] [Related]
4. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.
Cowling BS; Chevremont T; Prokic I; Kretz C; Ferry A; Coirault C; Koutsopoulos O; Laugel V; Romero NB; Laporte J
J Clin Invest; 2014 Mar; 124(3):1350-63. PubMed ID: 24569376
[TBL] [Abstract][Full Text] [Related]
5. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis.
Buj-Bello A; Fougerousse F; Schwab Y; Messaddeq N; Spehner D; Pierson CR; Durand M; Kretz C; Danos O; Douar AM; Beggs AH; Schultz P; Montus M; Denèfle P; Mandel JL
Hum Mol Genet; 2008 Jul; 17(14):2132-43. PubMed ID: 18434328
[TBL] [Abstract][Full Text] [Related]
6. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy.
Giraud Q; Spiegelhalter C; Messaddeq N; Laporte J
Brain; 2023 Oct; 146(10):4158-4173. PubMed ID: 37490306
[TBL] [Abstract][Full Text] [Related]
7. Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.
Mack DL; Poulard K; Goddard MA; Latournerie V; Snyder JM; Grange RW; Elverman MR; Denard J; Veron P; Buscara L; Le Bec C; Hogrel JY; Brezovec AG; Meng H; Yang L; Liu F; O'Callaghan M; Gopal N; Kelly VE; Smith BK; Strande JL; Mavilio F; Beggs AH; Mingozzi F; Lawlor MW; Buj-Bello A; Childers MK
Mol Ther; 2017 Apr; 25(4):839-854. PubMed ID: 28237839
[TBL] [Abstract][Full Text] [Related]
8. Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.
Silva-Rojas R; Nattarayan V; Jaque-Fernandez F; Gomez-Oca R; Menuet A; Reiss D; Goret M; Messaddeq N; Lionello VM; Kretz C; Cowling BS; Jacquemond V; Laporte J
Mol Ther; 2022 Feb; 30(2):868-880. PubMed ID: 34371181
[TBL] [Abstract][Full Text] [Related]
9. Intravenous Administration of a MTMR2-Encoding AAV Vector Ameliorates the Phenotype of Myotubular Myopathy in Mice.
Danièle N; Moal C; Julien L; Marinello M; Jamet T; Martin S; Vignaud A; Lawlor MW; Buj-Bello A
J Neuropathol Exp Neurol; 2018 Apr; 77(4):282-295. PubMed ID: 29408998
[TBL] [Abstract][Full Text] [Related]
10. Different in vivo impacts of dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or centronuclear myopathy.
Massana Muñoz X; Buono S; Koebel P; Laporte J; Cowling BS
Hum Mol Genet; 2019 Dec; 28(24):4067-4077. PubMed ID: 31628461
[TBL] [Abstract][Full Text] [Related]
11. The intragenic microRNA
Chen X; Gao YQ; Zheng YY; Wang W; Wang P; Liang J; Zhao W; Tao T; Sun J; Wei L; Li Y; Zhou Y; Gan Z; Zhang X; Chen HQ; Zhu MS
J Biol Chem; 2020 Jun; 295(26):8656-8667. PubMed ID: 32354746
[TBL] [Abstract][Full Text] [Related]
12. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.
Durieux AC; Vignaud A; Prudhon B; Viou MT; Beuvin M; Vassilopoulos S; Fraysse B; Ferry A; Lainé J; Romero NB; Guicheney P; Bitoun M
Hum Mol Genet; 2010 Dec; 19(24):4820-36. PubMed ID: 20858595
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness.
Cowling BS; Toussaint A; Amoasii L; Koebel P; Ferry A; Davignon L; Nishino I; Mandel JL; Laporte J
Am J Pathol; 2011 May; 178(5):2224-35. PubMed ID: 21514436
[TBL] [Abstract][Full Text] [Related]
14. Dynamin-2 reduction rescues the skeletal myopathy of a SPEG-deficient mouse model.
Li Q; Lin J; Widrick JJ; Luo S; Li G; Zhang Y; Laporte J; Perrella MA; Liu X; Agrawal PB
JCI Insight; 2022 Aug; 7(15):. PubMed ID: 35763354
[TBL] [Abstract][Full Text] [Related]
15. Sporadic centronuclear myopathy with muscle pseudohypertrophy, neutropenia, and necklace fibers due to a DNM2 mutation.
Liewluck T; Lovell TL; Bite AV; Engel AG
Neuromuscul Disord; 2010 Dec; 20(12):801-4. PubMed ID: 20817456
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.
Childers MK; Joubert R; Poulard K; Moal C; Grange RW; Doering JA; Lawlor MW; Rider BE; Jamet T; Danièle N; Martin S; Rivière C; Soker T; Hammer C; Van Wittenberghe L; Lockard M; Guan X; Goddard M; Mitchell E; Barber J; Williams JK; Mack DL; Furth ME; Vignaud A; Masurier C; Mavilio F; Moullier P; Beggs AH; Buj-Bello A
Sci Transl Med; 2014 Jan; 6(220):220ra10. PubMed ID: 24452262
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy.
Kierdaszuk B; Berdynski M; Karolczak J; Redowicz MJ; Zekanowski C; Kaminska AM
Neuromuscul Disord; 2013 Mar; 23(3):219-28. PubMed ID: 23374900
[TBL] [Abstract][Full Text] [Related]
18. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations.
Hanisch F; Müller T; Dietz A; Bitoun M; Kress W; Weis J; Stoltenburg G; Zierz S
J Neurol; 2011 Jun; 258(6):1085-90. PubMed ID: 21221624
[TBL] [Abstract][Full Text] [Related]
19. Dynamin 2 the rescue for centronuclear myopathy.
Demonbreun AR; McNally EM
J Clin Invest; 2014 Mar; 124(3):976-8. PubMed ID: 24569368
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of systemic gene therapy in a canine model of myotubular myopathy.
Elverman M; Goddard MA; Mack D; Snyder JM; Lawlor MW; Meng H; Beggs AH; Buj-Bello A; Poulard K; Marsh AP; Grange RW; Kelly VE; Childers MK
Muscle Nerve; 2017 Nov; 56(5):943-953. PubMed ID: 28370029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
